

AWARD NUMBER: W81XWH-13-1-0380

TITLE: "The Role of the New mTOR Complex, mTORC2, in Autism Spectrum Disorders"

PRINCIPAL INVESTIGATOR: Mauro Costa-Mattioli

CONTRACTING ORGANIZATION: Baylor College of Medicine
Houston, TX 77030

REPORT DATE: October 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2015		2. REPORT TYPE Annual		3. DATES COVERED 30Sep2014 - 29Sep2015	
4. TITLE AND SUBTITLE "The Role of the New mTOR Complex, mTORC2, in Autism Spectrum Disorders"				5a. CONTRACT NUMBER W81XWH-13-1-0380	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Mauro Costa-Mattioli E-Mail: costamat@bcm.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine One Baylor Plaza Houston, TX 77030-3498				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The goal of my DOD-supported research is determine the role of the new mTOR complex (mTORC2) in Autism Spectrum Disorder (ASD). ASD individuals exhibit impaired social interactions, seizures and abnormal repetitive behavior. In addition, 70-80% of autistic individuals suffer from mental retardation. Autism is a heritable genetically heterogeneous disorder and mutations in negative regulators of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, such as PTEN were associated with ASD. Here, we show that in the hippocampus of Pten fb-KO mice – where Pten is conditionally deleted in the murine forebrain – the activity of both mTORC1 and mTORC2 is increased. In addition, Pten fb-KO mice exhibit seizures, learning and memory, stereotype/repetitive behaviors and social deficits. Our remarkable preliminary data show that genetic inhibition of mTORC2, but not mTORC1, in Pten-deficient mice significantly promotes survival and seizures. In addition, Pten-ricor fb- double KO (DKO) mice, in which mTORC2 activity is restored to normal levels, EEG seizures, learning and memory as well as social phenotypes, are all rescued. We also found that in Pten-deficient mice mitochondria respiration is impaired and mTORC2 silencing restores mitochondria dynamics. In the third, year we will investigate the mechanism by which mTORC2 regulates mitochondria respiration. In addition, we will assess metabolic changes in neurons lacking Pten. These insights hold the promise for new mTORC2-based treatment of ASD.					
15. SUBJECT TERMS Autism Spectrum Disorder (ASD), mTORC2, mTORC1, protein synthesis, actin polymerization, mitochondria function, long-term memory, social behaviors, repetitive behaviors, and seizures.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
Unclassified	Unclassified	Unclassified	Unclassified	11	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords... ..	4
3. Overall Project Summary... ..	4
4. Key Research Accomplishments... ..	8
5. Conclusion... ..	9
6. Publications, Abstracts, and Presentations... ..	9
7. Inventions, Patents and Licenses.....	9
8. Reportable Outcomes.....	9
9. Other Achievements... ..	9
10. References.....	9
11. Appendices.....	11

1. Introduction:


Autism represents a heterogeneous group of disorders, which are defined as “autism spectrum disorders” (ASDs). ASD individuals exhibit common features such as impaired social interactions, language and communication, and abnormal repetitive behavior. In addition, 70-80% of autistic individuals suffer from mental retardation¹⁻³. The major goal of this award is to determine the role of mTORC2 in two mouse models of ASD. Recently, we have shown that mTORC2 plays a crucial role in long-term memory formation⁴. Briefly, mice lacking mTORC2 showed impaired long-lasting changes in synaptic strength (L-LTP) as well as impaired long-term memory (LTM). In addition, we have found that by promoting mTORC2 activity, with a new agent A-443654, it facilitates L-LTP and enhances long-term memory formation in WT mice. Interestingly, mTORC2 activity is altered in both ASD patients and ASD mouse models harboring mutation in *Tsc* and *Pten*^{5,6}. Hence, in this proposal we will test the hypothesis that the neurological dysfunction in several ASD mouse models is caused by dysregulation of mTORC2 rather than mTORC1 activity.

2. Keywords: Autism Spectrum Disorder (ASD), mTORC2, mTORC1, protein synthesis, actin polymerization, mitochondria function, long-term memory, social behaviors, repetitive behaviors, seizures.


3. Overall Project Summary. We have generated a remarkable amount of progress regarding specific Aim 2. The current view posit that in *Pten*-deficient mice increased mTORC1 activity is responsible for the behavioral, electrophysiological and pathophysiological abnormalities in these mice⁷. However, mTORC2 activity is also increased in *Pten*-deficient mice^{8,9}. Thus, we wondered whether reduction of either mTORC1 or mTORC2 could rescue the ASD-like cellular and behavioral endophenotypes in *PTEN*-deficient mice. To this end, we used genetic and conditionally deleted a) *Pten* and/or *riCTOR*, a defining mTORC2 component⁶, or b) *Pten* and/or *raptor*, a defining mTORC1 component, in the murine forebrain using the Cre/lox system. Because the α CaMKII promoter is inactive before birth^{10,11}, this manipulation rules out possible developmental defects caused by the lack of *pten*, *riCTOR* or *raptor*. We thus generated and studied the followings experimental mice: WT mice, *Pten* forebrain-specific knockout (here defined as *Pten* fb-KO), *Pten-riCTOR* forebrain-specific double knockout (here defined as *Pten-RiCTOR* fb-DKO) and *Pten-raptor* forebrain-specific KO (*Pten-Raptor* fb-DKO).

Specific inhibition of mTORC2 and mTORC1 activities in *Pten*-deficient mice.

According to our preliminary data, mTORC2-mediated phosphorylation of Akt at Ser473 (an established readout of mTORC2 activity⁶) and mTORC1-mediated phosphourylation of ribosome protein S6 (an established readout of mTORC1 activity)¹² were both increase in the hippocampus of *Pten* fb-KO. By contrast, in *Pten-RiCTOR* fb-DKO, while mTORC1 activity is up-regulated, mTORC2 activity is suppressed. In addition, in *Pten-Raptor* fb-DKO, mTORC2 activity is up-regulated by mTORC1 activity is suppressed. Hence, conditional deletion of *riCTOR* selectively blocks mTORC2 activity in *Pten*-deficient neurons and conditional deletion of *raptor* selectively block mTORC1 activity in *Pten*-deficient neurons.




Genetic inhibition of mTORC2, but not mTORC1 prolonged survival in *Pten*-deficient mice. Kaplan-Meier analysis of animal survival revealed a dramatic decreased in survival in *Pten* fb-KO mice (**Fig. 2**). Genetic elimination of raptor had no effect on *Pten* fb-KO mice survival (compare *Pten* fb-KO mice vs. *Pten-Raptor* DKO survival curves). Remarkably, genetic elimination of rictor significantly prolonged survival in *Pten*-deficient mice (compare *Pten* fb-KO mice vs. *Pten-Rictor* DKO survival curves; **Fig. 2**; *Pten-Rictor* fb-DKO die at an age of 119.4 +/- 25). Hence, inhibition of mTORC2, but not mTORC1, in *Pten*-deficient mice prolongs their survival.



Genetic inhibition of mTORC2, but not mTORC1 suppressed seizures in *Pten*-deficient mice.

Because patients with *Pten* mutations exhibit seizures, we next analyzed spontaneous seizures and abnormal electroencephalogram (EEG) activity. We found that *Pten* fb-KO mice show abnormal EEG as well as tonic-clonic seizures (**Fig. 3**). Consistent with the survival curves, *Pten-raptor* fb-DKO mice also showed tonic-clonic and EEG seizures. By contrast, while *Pten-Rictor* fb-DKO showed some abnormalities (spikes) in the EEG pattern, they did not show tonic-clonic and/or EEG seizures (**Fig. 3**). Thus, inhibition of mTORC2, but not mTORC1, suppresses the seizures EEG phenotype in *Pten*-deficient mice. Because in *Pten-raptor* fb-DKO mice genetic


inhibition of mTORC1 had not effect on seizures onset and duration and animal survival, in future experiments we focused on the characterization of *Pten*-rictor deficient mice.



Genetic inhibition of mTORC2 rescues LTM deficits in *Pten*-deficient mice.

Since emotions have a powerful impact on memory – most vivid autographical memories tend to be of emotional effects, and 70-80% of autistic individuals suffer from mental retardation¹⁻³, we first examined emotional memory. To this end, mice were first studied in contextual Pavlovian fear conditioning. Contextual fear conditioning, and hippocampus-dependent task, was induced by pairing a context (conditioned stimulus; CS) with a foot shock (the unconditioned stimulus; US). Mice were subsequently exposed to the auditory tone or visual stimulus (CS) and fear responses [mouse stop moving (“freezes”)] were taken as an index of the strength of memory (**Fig. 4a**). As expected, compared to control mice, *Pten* fb-KO mice showed impaired long-term fear memory (**Fig. 4b**). Strikingly, long-term memory is significantly improved in *Pten*-rictor fb-DKO mice. Thus, silencing mTORC2 activity restores LTM in *Pten*-deficient mice.

We next studied object recognition, another hippocampal dependent task. In this task, an object is presented to the subject mouse. After a 24 hr delay, the object is presented again with a new object (**Fig. 4c**). The time spent exploring each object is tracked via by a computer-operated optical animal activity system (ANIMAZE). We found that *Pten*-deficient mice failed to discriminate between and old and a new object (**Fig. 4d**). However, genetic deletion of rictor restore the object recognition long-term memory deficits in *Pten*-deficient mice.



Genetic inhibition of mTORC2 rescues social behaviors in *Pten*-deficient mice.

Given that social interaction deficits are salient features of ASD individuals², we next studied social behaviors. First, we assessed reciprocal social interactions by recording the amount of time a pair of mice spent interacting in a neutral arena¹³ (**Fig. 5a**). We found that compared to control mice, *Pten*-deficient mice showed reduced reciprocal interaction (**Fig. 5b**). Interestingly, in *Pten*-riCTOR DKO mice, reciprocal social interaction is normal. Next, we measured sociability and preference for social novelty using the Crawley 3-chamber test¹³ (**Fig. 5c, 5e**). In the sociability task, we compared the time a mouse spends interacting with an empty wired cage and one containing a mouse (**Fig. 5c**); whereas in the social novelty test, we measured the time a mouse spends interacting with a familiar or a stranger mouse (**Fig. 5e**). Consistent with the direct social interaction results, we found that *Pten* fb-KO mice had normal sociability (**Fig. 5d**), but showed no preference for interaction with a stranger versus a familiar mouse in the social novelty test (**Fig. 5f**). Strikingly, deletion of mTORC2 rescues the social novelty deficits in *Pten*-deficient mice (**Fig. 5f**). Taken together these data indicate that *Pten*-fb KO mice display social deficits and inhibition of mTORC2 restored their phenotypes.





Fig. 5. Social behaviors are normal in *Pten*-riCTOR fb-DKO mice. **a**) Schematic of reciprocal social interaction task. **b**, Compared to control or *pten*-riCTOR fb-DKO mice, *pten*-fb KO mice showed reduced reciprocal interaction. **c**, **e**, Schematic of three chamber social interaction task. **f**, Control mice spent most of the time interacting with the stranger mouse but *Pten* fb-KO mice spent equal time interacting with the familiar or strange mouse, indicating that social behavior is impaired in these mice. Like WT mice, *Pten*-riCTOR fb-KO mice spent more time interacting with the stranger mouse, indicating that social behavior is restored.


Genetic inhibition of mTORC2 rescues repetitive behaviors in *Pten*-deficient mice.

Because ASD patients also exhibit repetitive/stereotyped behavior behaviors, we first assessed marble burying. In this task, mice were individually placed in Plexiglas cages containing 5 cm deep fresh bedding, with 20 black marbles pre-arranged in 5x4 evenly spaced rows (**Fig. 6a**). Testing was conducted for 20 min. After the test period, unburied marbles were counted. We found that *Pten*-deficient mice buried more marbles than control mice, indicating repetitive behavior (**Fig. 6b**). Remarkably, deletion of rictor restored the repetitive behavior in *Pten*-deficient mice (**Fig. 6b**). We next assessed behavioral flexibility in the T-maze. In this task, normal animals tend to investigate first one and the other arm of the maze. Notably, *Pten*-deficient mice explored the same arm of the maze, demonstrating an impairment in behavioral flexibility. Remarkably, in *Pten*-riCTOR fb-DKO mice restored this behavior. Thus, taken together inhibition of mTORC2 restore memory, social and repetitive behaviors in *Pten*-deficient mice.



Genetic inhibition of mTORC2 restores mitochondria respiration in Pten-deficient mice.

Given that a) mitochondria dysfunction has been found in ASD patients¹⁴⁻¹⁶, b) Pten mutation affect mitochondria function¹⁷ and c) mTORC2 has been found in mitochondria¹⁸, we studied mitochondria respiration. We found that mitochondria respiration is impaired in Pten-deficient mice and genetic inhibition of mTORC2 restored it (**Fig. 7**). We will now investigate the precise mechanism by which mTORC2 silencing restores mitochondria function.



The goal of subaim-2 was to increase mTORC2 activity by treating Tsc2-deficient mice with the mTORC2 agonist A-443654⁴. We have obtained Tsc2 floxed mice but after breeding we noticed that they were in a mix background. Hence, to avoid any behavioral artifacts due to mixed genetic background, we decided to backcross these mice to C57BL6 mice to obtain a pure background. It is noteworthy that genetic background may alter behavior of autistic mice¹⁹. At least 8-10 generations are required to obtain mice in a pure background. We have so far backcrossed our mice 6 generation and in two generation we will cross our mice with CamKII-Cre. We will next treat the conditionalTsc2-deficient mice with vehicle and A-443654 and behavior and electrophysiology will be performed in these mice, as discussed in the proposal.

4. Key Research Accomplishment

- We developed a way to specifically block mTORC2 activity in Pten-deficient mice.
- We developed a way to specifically block mTORC1 activity in Pten-deficient mice
- Genetic deletion of mTORC2 prolongs the survival of Pten-deficient mice.
- Genetic deletion of mTORC2 dramatically attenuates seizures in Pten-deficient mice.
- Genetic deletion of mTORC2 improves cognitive and social phenotypes in Pten-deficient mice.
- Genetic deletion of mTORC2 improves repetitive behaviors.
- Genetic deletion of mTORC1 failed to restore animal's survival and seizures phenotype.

5. Conclusion

It has been proposed that the increased mTORC1 in Pten-deficient or Tsc-deficient mice causes the cellular and behavioral phenotypes associated with ASD²⁰⁻²⁶. Our new data challenge this view and provide causal evidence that inhibition of mTORC1 had no effect on Pten-induced physiopathology. More importantly, our data demonstrate that the neurological dysfunction in ASD, at least in the Pten-ASD mouse model, is caused by dysregulation of mTORC2. Hence, these preliminary data are very important since they identified a new signaling pathway involved in ASD and seizure disorders that could be targeted and lead to the development of new treatments for ASD and seizure disorders.

Future experiments: We will study the precise mechanism by which mTORC2 suppresses Pten-mediated cellular and behavioral phenotypes. We will focus on the mechanism by mTORC2 restores mitochondria respiration in Pten-deficient mice. Our preliminary experiments show that in Pten-deficient mice mitochondria respiration is reduced and deletion of mTORC2 restore its function. We will perform metabolomics in the hippocampus from Pten-deficient and Pten-*fb-DKO* mice. Finally, we will start to characterize the vehicle-treated and A-443654-treated Tsc-deficient mice in behavior and electrophysiology.

6. Publications

Some of these data described above were presented in

- “Catastrophic Epilepsy” at the Neurological Research Institute (NRI), Houston, Texas
- Symposium Society for Neuroscience (see 1: Huber KM, Klann E, Costa-Mattioli M, Zukin RS. Dysregulation of Mammalian Target of Rapamycin Signaling in Mouse Models of Autism. *J Neurosci*. 2015 Oct 14;35(41):13836-42. doi: 10.1523/JNEUROSCI.2656-15.2015. PubMed PMID: 26468183; PubMed Central PMCID: PMC4604222.)

7. Inventions, Patents and Licenses.

Nothing to report

8. Reportable Outcome

Nothing to report

9. Other achievements

We developed forebrain-specific rictor-Pten double KO mice.

We developed forebrain-specific raptor-Pten double KO mice.

10. References

- 1 Fombonne, E. The epidemiology of autism: a review. *Psychological medicine* **29**, 769-786 (1999).
- 2 Mefford, H. C., Batshaw, M. L. & Hoffman, E. P. Genomics, intellectual disability, and autism. *N Engl J Med* **366**, 733-743, doi:10.1056/NEJMra1114194 (2012).
- 3 Toro, R. *et al.* Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. *Trends Genet* **26**, 363-372, doi:S0168-9525(10)00107-1 [pii]10.1016/j.tig.2010.05.007 (2010).
- 4 Huang, W. *et al.* mTORC2 controls actin polymerization required for consolidation of long-term memory. *Nature neuroscience* **16**, 441-448, doi:10.1038/nn.3351 (2013).
- 5 Buffington, S. A., Huang, W. & Costa-Mattioli, M. Translational control in synaptic plasticity and cognitive dysfunction. *Annu Rev Neurosci* **37**, 17-38, doi:10.1146/annurev-neuro-071013-014100 (2014).

- 6 Costa-Mattioli, M. & Monteggia, L. M. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. *Nature neuroscience* **16**, 1537-1543, doi:10.1038/nn.3546 (2013).
- 7 Kelleher, R. J., 3rd & Bear, M. F. The autistic neuron: troubled translation? *Cell* **135**, 401-406, doi:S0092-8674(08)01308-1 [pii]10.1016/j.cell.2008.10.017 (2008).
- 8 Kwon, C. H. *et al.* Pten regulates neuronal arborization and social interaction in mice. *Neuron* **50**, 377-388, doi:S0896-6273(06)00220-0 [pii]10.1016/j.neuron.2006.03.023 (2006).
- 9 Zhou, J. *et al.* Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **29**, 1773-1783, doi:29/6/1773 [pii]10.1523/JNEUROSCI.5685-08.2009 (2009).
- 10 Mayford, M. *et al.* Control of memory formation through regulated expression of a CaMKII transgene. *Science* **274**, 1678-1683 (1996).
- 11 Tsien, J. Z. *et al.* Subregion- and cell type-restricted gene knockout in mouse brain. *Cell* **87**, 1317-1326 (1996).
- 12 Ma, X. M. & Blenis, J. Molecular mechanisms of mTOR-mediated translational control. *Nat Rev Mol Cell Biol* **10**, 307-318, doi:nrm2672 [pii]10.1038/nrm2672 (2009).
- 13 Silverman, J. L., Yang, M., Lord, C. & Crawley, J. N. Behavioural phenotyping assays for mouse models of autism. *Nature reviews. Neuroscience* **11**, 490-502, doi:nrn2851 [pii]10.1038/nrn2851 (2010).
- 14 Oliveira, G. *et al.* Mitochondrial dysfunction in autism spectrum disorders: a population-based study. *Developmental medicine and child neurology* **47**, 185-189 (2005).
- 15 Yui, K., Sato, A. & Imataka, G. Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders. *Mini reviews in medicinal chemistry* **15**, 373-389 (2015).
- 16 Legido, A., Jethva, R. & Goldenthal, M. J. Mitochondrial dysfunction in autism. *Seminars in pediatric neurology* **20**, 163-175, doi:10.1016/j.spen.2013.10.008 (2013).
- 17 Garcia-Cao, I. *et al.* Systemic elevation of PTEN induces a tumor-suppressive metabolic state. *Cell* **149**, 49-62, doi:10.1016/j.cell.2012.02.030 (2012).
- 18 Betz, C. *et al.* Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. *Proceedings of the National Academy of Sciences of the United States of America* **110**, 12526-12534, doi:10.1073/pnas.1302455110 (2013).
- 19 Moy, S. S. *et al.* Social approach in genetically engineered mouse lines relevant to autism. *Genes Brain Behav* **8**, 129-142, doi:10.1111/j.1601-183X.2008.00452.x (2009).
- 20 Ehninger, D. *et al.* Reversal of learning deficits in a Tsc2(+/-) mouse model of tuberous sclerosis. *Nature medicine* (2008).
- 21 Ehninger, D., de Vries, P. J. & Silva, A. J. From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. *Journal of intellectual disability research : JIDR* **53**, 838-851, doi:JIR1208 [pii]10.1111/j.1365-2788.2009.01208.x (2009).
- 22 Ehninger, D. & Silva, A. J. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. *Trends in molecular medicine* **17**, 78-87, doi:S1471-4914(10)00148-6 [pii]10.1016/j.molmed.2010.10.002 (2011).

- 23 Zhou, J. & Parada, L. F. PTEN signaling in autism spectrum disorders. *Current opinion in neurobiology*, doi:S0959-4388(12)00083-9 [pii]10.1016/j.conb.2012.05.004 (2012).
- 24 Carson, R. P., Van Nielen, D. L., Winzenburger, P. A. & Ess, K. C. Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin. *Neurobiology of disease* **45**, 369-380, doi:S0969-9961(11)00290-7 [pii]10.1016/j.nbd.2011.08.024 (2012).
- 25 Tsai, P. T. *et al.* Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. *Nature* **488**, 647-651, doi:nature11310 [pii]10.1038/nature11310 (2012).
- 26 Wong, M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. *Epilepsia* **51**, 27-36, doi:EPI2341 [pii]10.1111/j.1528-1167.2009.02341.x (2011).

11. Appendices

N/A